Key result
This review outlines the clinical evidence and perspectives on the efficacy of aldosterone-blocking agents, such as spironolactone and eplerenone, in treating heart failure and hypertension.
Why the study?
Do aldosterone blocking agents improve clinical outcomes in patients with heart failure and hypertension?
Do aldosterone blocking agents improve clinical outcomes in patients with heart failure and hypertension?
This review outlines the clinical evidence and perspectives for using aldosterone blocking agents like spironolactone and eplerenone in heart failure and hypertension.
Aldosterone blockade may benefit HF and hypertension patients; leaves open optimal agent selection amid newer therapies.
Aldosterone has an important role in end-organ damage in hypertension, post-MIcardiac remodelling, and heart failure. Accordingly blockers of the aldosterone receptor such as spironolactone and eplerenone have gained widespread use in the treatment of (post-MI) heart failure. The article outlines the clinical evidence on the efficacy of aldosterone blocking agents in heart failure and hypertension and outlines clinical perspectives for their use.
No takes yet. Share an insight, caveat, or question.
Böhm et al. (2011) conducted a review in Heart failure and hypertension. Aldosterone-blocking agents (spironolactone, eplerenone) was evaluated. This review outlines the clinical evidence and perspectives on the efficacy of aldosterone-blocking agents, such as spironolactone and eplerenone, in treating heart failure and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: